NCT00171041
Completed
Phase 3
A Double-Blind, Randomized, Multi-Center Study Followed By 12 Months Open-Label Treatment To Evaluate The Dose Response And Safety Of Valsartan In Pediatric Hypertensive Patients
ConditionsHypertension
Drugsvalsartan
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Hypertension
- Sponsor
- Novartis
- Enrollment
- 265
- Locations
- 1
- Primary Endpoint
- Change from baseline in sitting systolic blood pressure after 2 weeks
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
Drugs used to treat high blood pressure in adults should also be effective in treating high blood pressure in children and adolescents. This study will test the safety and efficacy of valsartan in treating high blood pressure in hypertensive children 6-16 years of age whose parent(s)/guardian(s) grant permission to participate.
Investigators
Eligibility Criteria
Inclusion Criteria
- •CHILDREN HAVE SYSTOLIC BLOOD PRESSURE AT A LEVEL =\>95th PERCENTILE FOR AGE/GENDER/HEIGHT
- •CONSENT FROM PARENT(S)/GUARDIAN(S) MUST BE GRANTED
Exclusion Criteria
- •BLOOD PESSURE IS =\>5% HIGHER THAN 99th PERCENTILE FOR AGE
- •SERIOUS, CLINICALLY SIGNIFICANT FINDINGS UPON PHYSICAL EXAMINATION, AND LABORATORY AND OTHER ASSESSMENTS
- •Other protocol-defined inclusion/exclusion criteria will also apply.
Outcomes
Primary Outcomes
Change from baseline in sitting systolic blood pressure after 2 weeks
Secondary Outcomes
- Change in diastolic blood pressure after 2 weeks to 4 weeks
- Change from baseline diastolic blood pressure after 2 weeks
- Change from baseline systolic blood pressure after 4 weeks
- Change from baseline diastolic blood pressure after 4 weeks
- Change from baseline systolic and diastolic blood pressure after 4 weeks and 52 weeks
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have HypertensionHypertensionNCT00171028Novartis90
Completed
Phase 3
Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)HypertensionNCT01286558Boehringer Ingelheim225
Completed
Phase 3
MK0954A-264 Filter Study (0954A-264)(COMPLETED)Mild to Severe HypertensionNCT00307060Organon and Co274
Unknown
Phase 3
Trial of Oral Melatonin in Elevated Blood PressureElevated Blood PressureNCT03764020Tehran University of Medical Sciences320
Completed
Phase 4
Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And HypertensionHypertensionNCT00060918GlaxoSmithKline1,210